我研究组前期经蛋白组学MALDI-TOF技术研究发现纤维蛋白原beta链多肽片段Bbeta10-42与Alpha链片段Aalpha522-552由正常肝组织向HBV感染肝炎、硬化及癌变过程中可能为新的临床辅助诊断标记物。本课题将进一步制备抗体进行临床血清学验证，并结合临床生化检验参数分析其辅助诊断价值；研究Bbeta10-42与Aalpha522-552在HBV感染肝脏病变中的病理学意义；检测外周血中纤维蛋白原降解相关酶（纤溶酶、凝血酶）活性、含量并分析它们与Bbeta10-42、Aalpha522-552的相互关系；探讨它们与免疫/炎症因子IFNgamma 、IL6、IL12、TNFalpha的关系，进一步挖掘它们可能的作用机制；并建立HBV感染肝脏疾病演变细胞模型，进行高Bbeta10-42、Aalpha522-552干预，验证其作用；最终通过生物信息学整合各类指标建立可用的诊断模型。

Previous our studies on proteomics by MALDI-TOF had found that the fragments of fibrinogen- Bbeta 10-42 (m/z 2883 Da) on beta chain and Aalpha 522-552 (m/z 4476 Da) on alpha?chain- possessed the auxiliary diagnostic value during HBV induced liver pathological changes. This study will move forward to preparing antibodies for Bbeta 10-42 and Aalpha 522-552 for further serological verification and analyzing their diagnostic values combined with other clinical parameters; detecting their pathological significances in the process of HBV induced liver diseases；comparing the relationships between Bbeta10-42/ Aalpha 522-552 and enzymes related with fibrinogen degradation (plasmin and thrombin); investigating their relationships with immune/inflammatory factors IFNgamma, IL6, IL12 and TNFalpha; thereafter verifying their functions by setting up the cellular model of high Bbeta10-42、Aalpha522-552；eventually by bioinformatic tools we can integrate all parameters and establish the diagnostic model for HBV infection.